Hostname: page-component-6898cfcb55-zkb6p Total loading time: 0 Render date: 2026-11-11T11:15:52.329Z Has data issue: false hasContentIssue false
  • English
  • Français

Viruses, chemotherapy and immunity

Published online by Cambridge University Press:  06 April 2009

M. J. Koziel and
B. D. Walker
M. J. Koziel
Affiliation:
Infectioús Disease Unit, Massachusetts General Hospital and Harvard Medical School, Fruit Street, Boston, MA 02114, USA
B. D. Walker
Affiliation:
Infectioús Disease Unit, Massachusetts General Hospital and Harvard Medical School, Fruit Street, Boston, MA 02114, USA
Get accessRights & Permissions [Opens in a new window]

Extract

An increasing number of antiviral agents are presently in various stages of development and testing, and an increasing number have recently been licensed for use in humans. These drugs have been used extensively to treat viral infections in immunocompromised individuals, and these studies indicate that for many antiviral agents the response to therapy is highly dependent on the integrity of the underlying host immune response. In particular, the response to zidovudine, acyclovir and ganciclovir in persons with HIV-1 infection is highly dependent upon CD4 number, which can be considered a surrogate marker for the state of host immune function in these subjects. Responses to interferons likewise can be shown to depend on the host immune response, with responses due to both direct antiviral effects of this agent as well as immunomodulatory effects mediated through interferon-induced upregulation of HLA molecule expression.

Keywords

viral diseasesimmune responseantiretroviral agentsinterferons

Information

Type
Research Article
Information
Parasitology , Volume 105 , Issue S1: Chemotherapy and the immune system , January 1992, pp. S85 - S92
Copyright
Copyright © Cambridge University Press 1992

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

REFERENCES

Blackman, M. J. & Morris, A. G. (1985). The effect of interferon treatment of targets on susceptibility to cytotoxic T-lymphocyte killing: augmentation of allogeneic killing and virus-specific killing relative to viral antigen expression. Immunology 56, 451–7.Google ScholarPubMed
Connolly, K. J., Allan, J. D., Fitch, H., Jackson, P. L., McLaren, C., Canetta, R. & Groopman, J. E. (1991).Phase I study of 2′-3′-dideoxyinosine administered orally twice daily to patients with AIDS or AIDS-related complex and hematologic intolerance to zidovudine. American Journal of Medicine 91, 471–8.CrossRefGoogle ScholarPubMed
Cooley, T. P., Kunches, L. M., Saunders, C. A., Perkins, C. J., Kelley, S. L., McLaren, C., McCaffrey, R. P. & Liebman, H. A. (1990 a). Treatment of AIDS and AIDS-related complex with 2′,3′-dideoxyinosine given once daily. Reviews of Infectious Diseases 5, S552–60.CrossRefGoogle Scholar
Cooley, T. P., Kunches, L. M., Saunders, C. A., Ritter, J. K., Perkins, C. J., McLaren, C., McCaffrey, R. P. & Liebman, H. A. (1990b). Once-daily administration of 2′,3′-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. New England Journal of Medicine 322, 1340–5.CrossRefGoogle ScholarPubMed
Cooper, D. A. and The European—American Collaborative Group (1992). The efficacy and safety of zidovudine therapy in early asymptomatic HIV infection. VIIIth International Conference on AIDS, Amsterdam, 1992 (abstract).Google Scholar
di Bisceglie, A. M., Martin, P., Kassianides, C., Lisker, M. M., Goodman, Z., Banks, S. M. & Hoofnagle, J. H. (1990). A randomized, double-blind, placebo-controlled trial of recombinant human alpha-interferon therapy for chronic non-A, non-B (type C) hepatitis. Journal of Hepatology 1, 1506–10.Google Scholar
Drew, W. L. (1991). Clinical use of ganciclovir for cytomegalovirus infection and the development of drug resistance. Journal of the Acquired Immune Deficiency Syndromes 1, S42–6.Google Scholar
Englund, J. A., Zimmerman, M. E., Swierkosz, E. M., Goodman, J. L., Scholl, D. R. & Balfour, H. H. J. (1990). Herpes simplex virus resistant to acyclovir. A study in a tertiary care center. Annals of Internal Medicine 112, 416–22.CrossRefGoogle ScholarPubMed
Evans, L. M., Itri, L. M., Campion, M., Wyler, P. R., Krown, S. E., Groopman, J. E., Goldswieg, H., Volberding, P. A., West, S. B. & Mitsuyasu, R. T. (1991). Interferon-alpha 2a in the treatment of acquired immunodeficiency syndrome-related Kaposi's sarcoma. Journal of Immunotherapy 10, 39–50.CrossRefGoogle ScholarPubMed
Farci, P., Alter, H., Govindarajan, S., Wong, D., Engle, R., Lesniewski, R., Mushahwar, I., Desai, S., Miller, R., Ogata, N. & Purcell, R. H. (1992). Lack of protective immunity against reinfection with hepatitis C virus. Science 258, 135–40.CrossRefGoogle ScholarPubMed
Fauci, A. S., Schnittman, S. M., Poli, G., Koenig, S. & Pantaleo, G. (1991). NIH conference. Immunopathogenic mechanisms in human immunodeficiency virus (HIV) infection. Annals of Internal Medicine 114, 678–93.CrossRefGoogle ScholarPubMed
Finter, N. B., Chapman, S., Dowd, P., Johnston, J. M., Manna, V., Sarantis, N., Sheron, N., Scott, G., Phua, S. & Tatum, P. B. (1991). The use of interferon-alpha in virus infections. Drugs 42, 749–65.CrossRefGoogle ScholarPubMed
Fischl, M. A., Richman, D. D., Grieco, M. H., Gottlieb, M. S., Volberding, P. A., Laskin, O. L., Leedom, J. M., Groopman, J. E., Mildvan, D. & Schooley, R. T. (1987). The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. New England Journal of Medicine 317, 185–91.CrossRefGoogle ScholarPubMed
Furman, P. A., Fyfe, J. A., st Clair, M. H., Weinhold, K., Rideout, J. L., Freeman, G. A., Lehrman, S. N., Bolognesi, D. P., Broder, S. & Mitsuya, H. (1986). Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase. Proceedings of the National Academy of Sciences, USA 83, 8333–7.CrossRefGoogle ScholarPubMed
Gartner, S., Markovits, P., Markovits, D. M., Kaplan, M. H., Gallo, R. C. & Popovic, M. (1986). The role of mononuclear phagocytes in HTLV-III/LAV infection. Science 233, 215–19.CrossRefGoogle ScholarPubMed
Gendelman, H. E., Orenstein, J. M., Martin, M. A., Ferrua, C., Mitra, R., Phipps, T., Wahl, L. A., Lane, H. C., Fauci, A. S. & Burke, D. S. (1988). Efficient isolation and propagation of human immunodeficiency virus on recombinant colony-stimulating factor 1-treated monocytes. Journal of Experimental Medicine 167, 1428–41..CrossRefGoogle ScholarPubMed
Graham, N. M., Zeger, S. L., Park, L. P., Vermund, S. H., Detels, R., Rinaldo, C. R. & Phair, J. P. (1992). The effects on survival of early treatment of human immunodeficiency virus infection. New England Journal of Medicine 326, 1037–42.CrossRefGoogle ScholarPubMed
Hayata, T., Nakano, Y., Yoshizawa, K., Sodeyama, T. & Kiyosawa, K. (1991). Effects of interferon on intrahepatic human leukocyte antigens and lymphocyte subsets in patients with chronic hepatitis B and C. Hepatology 13, 1022–8.CrossRefGoogle ScholarPubMed
Heagy, W., Crumpacker, C., Lopez, P. A. & Finberg, R. W. (1991). Inhibition of immune functions by antiviral drugs. Journal of Clinical Investigation 87, 1916–24.CrossRefGoogle ScholarPubMed
Hirsch, M. S. & D'Aquila, R. (1993). Treatment of human immunodeficiency virus infection. New England Journal of Medicine (In the Press).Google ScholarPubMed
Hoxie, J. A., Haggarty, B. S., Rackowski, J. L., Pillsbury, N. & Levy, J. A. (1985). Persistent noncytopathic infection of normal human T lymphocytes with AIDS-associated retrovirus. Science 229, 1400–2.CrossRefGoogle Scholar
Jacobson, M. A., Berger, T. G., Fikrig, S., Becherer, P., Moohr, J. W., Stanat, S. C. & Biron, K. K. (1990).Acyclovir-resistant varicella zoster virus infection after chronic oral acyclovir therapy in patients with the acquired immunodeficiency syndrome (Al DS). Annals of Internal Medicine 112, 187–91.CrossRefGoogle Scholar
Jassoy, C., Johnson, R. P., Navia, B. A., Worth, J. & Walker, B. D. (1992). Detection of a vigorous HIV-1-specific cytotoxic T lymphocyte response in the cerebrospinal fluid of infected persons with AIDS dementia complex. Journal of Immunology 149, 3113–119.CrossRefGoogle ScholarPubMed
Jassay, C., Harrer, T., Rosenthal, T., Navia, B. A., Worth, J., Johnson, R. P. & Walker, B.D. (1993). Human immunodeficiency virus type 1-specific cytotoxic T lymphocytes release gamma interferon, tumor necrosis factor alpha (TNF-α), and TNF-β when they encounter their target antigens. Journal of Virology 67, 2844–52.CrossRefGoogle Scholar
Johnson, V. A., Merrill, D. P., Videler, J. A., Chou, T. C., Byington, R. E., Eron, J. J., D'Aquila, R. T. & Hirsch, M. S. (1991). Two-drug combinations of zidovudine, didanosine, and recombinant interferon-alpha A inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in vitro. Journal of Infectious Diseases 164, 646–55.CrossRefGoogle ScholarPubMed
Joly, E.., Mucke, L. & Oldstone, M. B. (1991). Viral persistence in neurons explained by lack of major histocompatibility class I expression. Science 253, 1283–5.CrossRefGoogle ScholarPubMed
Kahn, J. O., Lagakos, S., Richman, D., Cross, A., Pettinelli, C., Liou, S.-H., Brown, M., Volberding, P., Crumpacker, C., Beall, G., Sacks, H., Merigan, T. C., Beltangady, M., Smaldone, L., Dolin, R. & The National Aids Clinical Trials Group (1992). A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. New England Journal of Medicine 327, 581–7.CrossRefGoogle ScholarPubMed
Koziel, M. J., Dudley, D., Wong, J., Dienstag, J., Houghton, M., Ralston, R. & Walker, B. D. (1992). Intrahepatic cytotoxic T lymphocytes specific for hepatitis C virus in persons with chronic hepatitis. Journal of Immunology 149, 3339–44.CrossRefGoogle ScholarPubMed
Krown, S. E. (1991). Interferon and other biologic agents for the treatment of Kaposi's sarcoma. Hematology/Oncology Clinics of North America 5, 311–22.CrossRefGoogle ScholarPubMed
Lambert, J. S., Seidlin, M., Reichman, R. C., Plank, C. S., Laverty, M., Morse, G. D., Knupp, C., McLaren, C., Pettinelli, C. & Valentine, F. J. (1990). 2′,3′-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. New England Journal of Medicine 322, 1333–40.CrossRefGoogle ScholarPubMed
Lane, H. C. (1991). A phase I/II trial of zidovudine, interferon-alpha, and granulocyte-macrophage colony-stimulating factor in the treatment of human immunodeficiency virus type 1 infection. Journal of Infectious Diseases 164, 43–52.Google Scholar
Larder, B. A., Darby, G. & Richman, D. D. (1989). HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 243, 1731–4.CrossRefGoogle ScholarPubMed
Lobbiani, A., Lalatta, F., Lugo, F. & Colucci, G. (1990). Hepatitis B virus transcripts and surface antigen in human peripheral blood lymphocytes. Journal of Medical Virology 31, 190–4.CrossRefGoogle ScholarPubMed
McMichael, A. J., Gotch, F. M., Noble, G. R. & Beare, P. A. (1983). Cytotoxic T-cell immunity to influenza. New England Journal of Medicine 309, 13–17.CrossRefGoogle ScholarPubMed
Masur, H. (1992). New advances in the management of AIDS associated opportunistic infections. Aids Research and Human Retroviruses 8, 728–31.Google ScholarPubMed
Mitsuyasu, R. T. (1991). Interferon alpha in the treatment of AIDS-related Kaposi's sarcoma. British Journal of Haematology 1, 69–73.CrossRefGoogle Scholar
Moore, R. D., Keruly, J., Richman, D. D., Creagh, K. T. & Chaisson, R. E. (1992). Natural history of advanced HIV disease in patients treated with zidovudine. The Zidovudine Epidemiology Study Group. AIDS 6, 671–7.CrossRefGoogle ScholarPubMed
Moriyama, T., Guilhot, S., Klopchin, K., Moss, B., Pinkert, C., Palmiter, R., Brinster, R., Kanagawa, O. & Chisari, F. (1990). Immunobiology and pathogenesis of hepatocellular injury in transgenic mice. Science 248, 361–4.CrossRefGoogle ScholarPubMed
Morris, A. G., Lin, Y. L. & Askonas, B. A. (1982). Immune interferon release when a cloned cytotoxic T-cell line meets its correct influenza-infected target cell. Nature 295, 150–2.CrossRefGoogle Scholar
Pantaleo, G., Graziosi, C. & Fauci, A. S. (1993). Mechanisms of disease: the immunopathogenesis of human immunodeficiency virus infection. New England Journal of Medicine 328, 327–35.Google Scholar
Perrillo, R. P., Schiff, E. R., Davis, G. L., Bodenheimer, H. C. J., Lindsay, K., Payne, J., Dienstag, J. L., O'Brien, C., Tamburro, C. & Jacobson, I. M. (1990). A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. New England Journal of Medicine 323, 295–301.CrossRefGoogle ScholarPubMed
Polk, B. F., Fox, R., Brookmeyer, R., Kancharnaraksa, S., Kaslow, R., Visscher, B., Rinaldo, C. & Phair, J. (1987). Predictors of the acquired immunodeficiency syndrome developing in a cohort of seropositive homosexual men. New England Journal of Medicine 316, 61–6.CrossRefGoogle Scholar
Prince, A., Brotman, B., Hiuma, T., Pascual, D., Jaffery, M. & Inchauspe, G. (1992). Immunity in hepatitis C infection. Journal of Infectious Diseases 165, 438–43.CrossRefGoogle ScholarPubMed
Quinnan, G. V. J., Kirmani, N., Rook, A. H., Manischewitz, J. F., Jackson, L., Moreschi, G., Santos, G. W., Saral, R. & Burns, W. H. (1982). Cytotoxic t cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-Iymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients. New England Journal of Medicine 307, 7–13.CrossRefGoogle ScholarPubMed
Richman, D. D., Fischl, M. A., Grieco, M. H., Gottlieb, M. S., Volberding, P. A., Laskin, O. L., Leedom, J. M., Groopman, J. E., Mildvan, D. & Hirsch, M. S. (1987). The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. New England Journal of Medicine 317, 192–7.CrossRefGoogle ScholarPubMed
Rooke, R., Tremblay, M., Soudeyns, H., Destephano, L., Yao, X. Y., Fanning, M., Montaner, J. S., O'Shaughnessy, M., Gelmon, K. & Tsoukas, C. (1989). Isolation of drug-resistant variants of HIV-1 from patients on long-term zidovudine therapy. Canadian Zidovudine Multi-Centre Study Group. AIDS 3, 411–15.CrossRefGoogle ScholarPubMed
Samuel, C. (1991). Antiviral actions of interferon: Interferon-regulated cellular proteins and their surprisingly selective antiviral activities. Virology 183, 1–11.CrossRefGoogle ScholarPubMed
Schmitt, F. A., Bigley, W. & McKinnis, R. (1988). Neuropsychological outcome of zidovudine (AZT) treatment of patients with AIDS and AIDS-related complex. New England Journal of Medicine 319, 1573–8.CrossRefGoogle ScholarPubMed
Schooley, R. T. (1990). Cytomegalovirus in the setting of infection with human immunodeficiency virus. Reviews of Infectious Diseases 7, S811–19.CrossRefGoogle Scholar
Sethi, K. K., Naher, H. & Stroehmann, I. (1988). Phenotypic heterogeneity of cerebrospinal fluid-derived HIV-specific and HLA-restricted cytotoxic T-cell clones. Nature 335, 178–81.CrossRefGoogle ScholarPubMed
Shindo, M., Di, B. A. M., Cheung, L., Shih, J. W., Cristiano, K., Feinstone, S. M. & Hoofnagle, J. H. (1991). Decrease in serum hepatitis C viral RNA during alpha-interferon therapy for chronic hepatitis C. Annals of Internal Medicine 115, 700–4.CrossRefGoogle ScholarPubMed
st Clair, M. H., Martin, J. L., Tudor, W. G., Bach, M. C., Vavro, C. L., King, D. M., Kellam, P., Kemp, S. D. & Larder, B. A. (1991). Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 253, 1557–9.CrossRefGoogle ScholarPubMed
Stanat, S. C., Reardon, J. E., Erice, A., Jordan, M. C., Drew, W. L. & Biron, K. K. (1991). Ganciclovir-resistant cytomegalovirus clinical isolates: mode of resistance to ganciclovir. Antimicrobial Agents and Chemotherapy 35, 2191–7.CrossRefGoogle ScholarPubMed
Taliani, G., Lecce, R., Clementi, C., Furlan, C. & De, B. C. (1991). Antiviral actions of interferon. Interferon-regulated cellular proteins and their surprisingly selective antiviral activities. Virology 183, 1–11.Google Scholar
Townsend, A. R., Rothbard, J., Gotch, F. M., Bahadur, G., Wraith, D. & McMichael, A. J. (1986). The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell 44, 959–68.CrossRefGoogle ScholarPubMed
Tudor-Williams, G., st Clair, M. H., McKinney, R. E., Maha, M., Walter, E., Santacroce, S., Mintz, M., O'Donnell, K., Rudoll, T. & Vavro, C. L. (1992). HIV-1 sensitivity to zidovudine and clinical outcome in children. Lancet 339, 15–19.CrossRefGoogle ScholarPubMed
Vella, S., Giuliano, M., Pezzotti, P., Agresti, M. G., Tomino, C., Floridia, M., Greco, D., Moroni, M., Visco, G. & Milazzo, F. (1992). Survival of zidovudine-treated patients with AIDS compared with that of contemporary untreated patients. Italian Zidovudine Evaluation Group. Journal of the American Medical Association 267, 1232–6.CrossRefGoogle ScholarPubMed
Volberding, P. A., Lagakos, S. W., Koch, M. A., Pettinelli, C., Myers, M. W., Booth, D. K., Balfour, H. H. J., Reichman, R. C., Bartlett, J. A. & Hirsch, M. S. (1990). Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. New England Journal of Medicine 322, 941–9.CrossRefGoogle ScholarPubMed
Whitley, R. J., Alford, C. A., Hirsch, M. S., Schooley, R. T., Luby, J. P., Aoki, F. Y., Hanley, D., Nahmias, A. J. & Soong, S. J. (1986). Vidarabine versus acyclovir therapy in herpes simplex encephalitis. New England Journal of Medicine 314, 144–9.CrossRefGoogle ScholarPubMed
Whitley, R. J. & Gnann, J. W. J. (1992). Acyclovir: A decade later. New England Journal of Medicine 327, 782–9.Google ScholarPubMed
Yap, K. L., Ada, G. L. & McKenzie, I. F. (1978). Transfer of specific cytotoxic T lymphocytes protects mice inoculated with influenza virus. Nature 273, 238–9.CrossRefGoogle ScholarPubMed
Yarchoan, R., Klecker, R. W., Weinhold, K. J., Markham, P. D., Lyerly, H. K., Durack, D. T., Gelmann, E., Lehrman, S. N., Blum, R. M. & Barry, D. W. (1986). Administration of 3′-azido-3′-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex. Lancet 1, 575–80.CrossRefGoogle ScholarPubMed
Yarchoan, R., Venzon, D. J., Pluda, J. M., Lietzau, J., Wyvill, K. M., Tsiatis, A. A., Steinberg, S. M. & Broder, S. (1991). CD4 count and the risk for death in patients infected with HIV receiving antiretroviral therapy. Annals of Internal Medicine 115, 184–9.CrossRefGoogle ScholarPubMed